New clinical data on lecanemab to be presented at CTAD conference 2026

Barchart · 1d ago

STOCKHOLM, October 30, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, November 16-19, 2026. The presentations will include five-year data from the Clarity AD study, as well as findings from the real-world LEADER study in diverse US clinical settings. In addition, BioArctic will present a poster on the binding profile of lecanemab.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.